Genprex Announces Preclinical Data for TUSC2 Immunogene Therapy in Non-Small Cell Lung Cancer to Be Featured in Two Presentat...
March 30 2021 - 8:30AM
Business Wire
Two Featured Presentations will Highlight
Potential of TUSC2 Immunogene Therapy to Enhance Chemo-Immune
Combination Treatments and Overcome Resistance to Osimertinib
Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a
clinical-stage gene therapy company focused on developing
life-changing therapies for patients with cancer and diabetes,
today announced that preclinical data of its TUSC2 immunogene
therapy (REQORSA™) in combination with chemotherapy and
immunotherapies, as well as in combination with targeted therapies
to overcome resistance to osimertinib, for the treatment of
non-small cell lung cancer (NSCLC), will be featured in two
presentations at the upcoming annual meeting of the American
Association for Cancer Research (AACR 21) taking place virtually
from April 9-14, 2021.
“We look forward to the presentation of these data that
highlight the potential of TUSC2 immunogene therapy to enhance
chemo-immune combination treatments and overcome resistance to
osimertinib in lung cancer, to an audience of the world’s leading
cancer researchers,” said Rodney Varner, President and Chief
Executive Officer of Genprex. “As lung cancer is the leading cause
of cancer deaths worldwide, we remain keenly focused on initiating
our Acclaim-1 and Acclaim-2 clinical trials to evaluate REQORSA,
our proprietary TUSC2 immunogene therapy, in non-small cell lung
cancer.”
Acclaim-1 is a Phase 1/2 combination clinical trial using
REQORSA combined with AstraZeneca’s Tagrisso® (osimertinib) in
patients with late-stage NSCLC whose disease progressed after
treatment with Tagrisso. Acclaim-2 is a Phase 1/2 combination
clinical trial using REQORSA combined with Merck & Co’s
Keytruda® (pembrolizumab) in NSCLC patients who are low expressors
of PD-L1.
Featured Genprex-supported abstracts to be presented at AACR 21
include:
Oral
Presentation
Session:
MS.IM02.02 - Overcoming Resistance in the
Tumor Microenvironment: Novel Immunomodulatory Agents
Title:
“TUSC2 immunogene therapy enhances
efficacy of chemo-immune combination therapy and induces robust
antitumor immunity in KRAS-LKB1 mutant NSCLC in humanized mice”
Poster Number/Channel:
#76/Channel 03
Presentation Date/Time:
April 10, 2021 from 2:50-3:00 p.m. ET
Presenters:
Ismail M. Meraz, Mourad Majidi, RuPing
Shao, Feng Meng, Min Jin Ha, Elizabeth Shpall, Jack A. Roth.
University of Texas MD Anderson Cancer Center, Houston, TX
Poster
Presentation:
Session:
PO.ET03.01 - Drug Resistance in Molecular
Targeted Therapies
Title:
“Overcoming resistance to osimertinib by
TUSC2 gene therapy in EGFR mutant NSCLC”
Poster Number:
#1105
Presentation Date/Time:
April 10, 2021 from 8:30 a.m. - 11:59 p.m.
ET
Presenters:
Ismail M. Meraz, Mourad Majidi, RuPing
Shao, Lihui Gao, Meng Feng, Huiqin Chen, Min Jin Ha, Jack A. Roth.
University of Texas MD Anderson Cancer Center, Houston, TX
About Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company focused
on developing life-changing therapies for patients with cancer and
diabetes. Genprex’s technologies are designed to administer
disease-fighting genes to provide new therapies for large patient
populations with cancer and diabetes who currently have limited
treatment options. Genprex works with world-class institutions and
collaborators to develop drug candidates to further its pipeline of
gene therapies in order to provide novel treatment approaches. The
Company’s lead product candidate, REQORSA™ (quaratusugene
ozeplasmid), is being evaluated as a treatment for non-small cell
lung cancer (NSCLC). REQORSA has a multimodal mechanism of action
that has been shown to interrupt cell signaling pathways that cause
replication and proliferation of cancer cells; re-establish
pathways for apoptosis, or programmed cell death, in cancer cells;
and modulate the immune response against cancer cells. REQORSA has
also been shown to block mechanisms that create drug resistance. In
January 2020, the U.S. Food and Drug Administration granted Fast
Track Designation for REQORSA for NSCLC in combination therapy with
osimertinib (AstraZeneca’s Tagrisso®) for patients with EFGR
mutations whose tumors progressed after treatment with osimertinib
alone.
For more information, please visit the Company’s web site at
www.genprex.com or follow Genprex on Twitter, Facebook and
LinkedIn.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Such
statements include, but are not limited to, statements regarding
the effect of Genprex’s product candidates, alone and in
combination with other therapies, on cancer and diabetes, regarding
potential, current and planned clinical trials, regarding the
Company’s future growth and financial status and regarding our
commercial partnerships and intellectual property licenses. Risks
that contribute to the uncertain nature of the forward-looking
statements include the presence and level of the effect of our
product candidates, alone and in combination with other therapies,
on cancer; the timing and success of our clinical trials and
planned clinical trials of REQORSA™ immunogene therapy drug, alone
and in combination with targeted therapies and/or immunotherapies,
and whether our other potential product candidates, including
GPX-002, our gene therapy in diabetes, advance into clinical
trials; the success of our strategic partnerships, including those
relating to manufacturing of our product candidates; the timing and
success at all of obtaining FDA approval of REQORSA and our other
potential product candidates including whether we receive or
benefit from fast track or similar regulatory designations; costs
associated with developing our product candidates, whether we
identify and succeed in acquiring other technologies and whether
patents will ever be issued under patent applications that are the
subject of our license agreements or otherwise. These and other
risks and uncertainties are described more fully under the caption
“Risk Factors” and elsewhere in our filings and reports with the
United States Securities and Exchange Commission. All
forward-looking statements contained in this press release speak
only as of the date on which they were made. We undertake no
obligation to update such statements to reflect events that occur
or circumstances that exist after the date on which they were
made.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210330005243/en/
Genprex, Inc. (877) 774-GNPX (4679)
Investor Relations GNPX Investor Relations (877) 774-GNPX
(4679) ext. #2 investors@genprex.com
Media Contact Genprex Media Relations Kalyn Dabbs (877)
774-GNPX (4679) ext. #3 media@genprex.com
Genprex (NASDAQ:GNPX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Genprex (NASDAQ:GNPX)
Historical Stock Chart
From Sep 2023 to Sep 2024